A promising new pancreatic cancer drug that nearly doubled survival times in a recent clinical trial is drawing attention not only for its potential impact on patients, but also for the university research that helped make it possible. In recent clinical trials by oncology company Revolution Medicines, patients who received daraxonrasib live an average of 13.